Erythroferrone Hormone a Novel Biomarker is associated with Anemia and Iron Overload in Beta Thalassemia Patients.

Abstract

Abstract Erythroferrone (ERFE) is a glycoprotein hormone produced by erythroblasts in response to erythropoietic activity by stimulation of erythropoietin that acts directly on the liver to inhibit production of hepcidin, lead to increases iron delivery for intensified activity of erythropoietic. Beta thalassemia are inherited disorders characterized by reduced or absent synthesis of beta globin chains in the hemoglobin (Hb) molecule1 The pathophysiology has been recognized by anemia and iron overload continually with resultant of frequented blood transfusions. We intend to investigate serum ERFE level and their associations with each other. Beta Thalassemia (BT) patients, who were inspected at thalassemia center in ALzahraà hospital teaching period transfusions blood (PTB) for each (14-30 day). Seventy patients were aged about (11-28 year) and 20 subjects healthy as control group, who matched were included in the study. Results. Serum ERFE levels were significantly higher in BT patients compared to control groups. There were significantly (p<0.05) differences in these biomarker between (BTM and BTI), (splenectomy and non splenectomy) groups. a negative correlation between ERFE levels with HB, PCV, MCV, MCH, Iron, and Ferritin while it was a not significant correlated with MCHC and PTB. High level of ERFE as new biomarker in patients with BTM and BTI is associated with mild or severe anemia and iron overload especially in patients with splenectomy.